Compare MPV & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | CCCC |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 185.1M |
| IPO Year | N/A | 2020 |
| Metric | MPV | CCCC |
|---|---|---|
| Price | $19.08 | $2.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 9.5K | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $15.22 | $1.09 |
| 52 Week High | $21.00 | $3.82 |
| Indicator | MPV | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 53.55 |
| Support Level | $18.64 | $2.14 |
| Resistance Level | $19.54 | N/A |
| Average True Range (ATR) | 0.34 | 0.34 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 78.95 | 38.82 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.